Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lifted by research analysts at Royal Bank of Canada from $310.00 to $330.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 17.54% from the company’s current price.

ALNY has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Sanford C. Bernstein dropped their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $309.61.

Alnylam Pharmaceuticals Trading Up 10.7 %

NASDAQ ALNY traded up $27.20 during mid-day trading on Friday, reaching $280.75. 1,794,610 shares of the stock were exchanged, compared to its average volume of 796,523. The stock has a market capitalization of $36.34 billion, a PE ratio of -129.40 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The business’s fifty day simple moving average is $256.25 and its 200 day simple moving average is $259.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $33,000. Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.